Absci reports safe hair loss drug results, targeting $25 billion market

Absci Corporation presented interim Phase I/II data for its hair-loss treatment, ABS-201, at the Morgan Stanley Global Healthcare Conference. The study reported no serious adverse events among 32 volunteers. The treatment demonstrated an estimated half-life of at least 65 days.

Management highlighted an AI-driven platform designed to reduce drug development timelines and costs. Absci estimates the U.S. market for pattern hair loss exceeds $25 billion.

The company maintains a cash runway into the second half of 2028. This position follows a $40 million strategic investment from Eli Lilly. Investors expect key efficacy data in December.